Kronos Bio Stock Discussion

$Kronos Bio (KRON.US)$
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

$Kronos Bio (KRON.US)$
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
Kronos Bio (NASDAQ: KRON) presented preclinical data from its p300 KAT inhibitor program for HPV-driven tumors at the EORTC-NCI-AACR Symposium. The research demonstrates that their p300 KAT inhibitor, KB-9558, effectively suppresses HPV oncogenes E6 and E7, which are critical for tumor growth. The inhibition leads to restoration of p53 and Rb tu...

$Kronos Bio (KRON.US)$
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
Kronos Bio (Nasdaq: KRON) will present preclinical data on its p300 KAT inhibitor program for HPV-driven tumors at the EORTC-NCI-AACR Symposium in Barcelona, Spain, from October 23-25, 2024. The company's p300 KAT inhibitor, KB-9558, shows promise in targeting HPV-driven cancers by selectively inhibiting viral oncoproteins E6 and E7.
Key findings include:
HP...

$Kronos Bio (KRON.US)$
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
Kronos Bio has announced the selection of KB-7898, a p300 KAT inhibitor, as its first development candidate for autoimmune diseases, specifically targeting Sjögren’s disease. This candidate stems from Kronos Bio's proprietary discovery engine, which decodes complex transcription factor regulatory networks.
Preclinical data for KB-7898 will be presented at ACR Convergence 2024. The d...

$Kronos Bio (KRON.US)$
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
Kronos Bio (Nasdaq: KRON) will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at ACR Convergence 2024 in Washington, DC. The presentation, scheduled for November 18, 2024, will showcase how p300 KAT inhibitionmodulates multiple pro-inflammatory signaling pathways in chronic inflammatory diseases.
The compa...

$Kronos Bio (KRON.US)$ Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
4 MINUTES AGO, 8:55 AM EDT
VIA GLOBENEWSWIRE
– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance –
New PK/PD results demonstrate that istisociclib given at 80mg on a 4 days on/3 days off schedule resulted in sustained downregulati...

$Kronos Bio (KRON.US)$
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
Kronos Bio (NASDAQ: KRON) presented new preclinical data on istisociclib (KB-0742), a CDK9 inhibitor, at the AACR Ovarian Cancer Research Symposium. The data supports the clinical evaluation of istisociclib in advanced ovarian cancer, particularly in platinum and PARP-inhibitor resistant cases.
Key findings include:
Istisocic...

$Kronos Bio (KRON.US)$
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
Kronos Bio (NASDAQ: KRON) has dosed the first patient in an expansion cohort of its KB-0742 clinical trial, focusing on platinum-resistant high-grade serous ovarian cancer (HGSOC). The trial uses an 80mg dose on a four-days-on, three-days-off schedule, which cleared the dose escalation phase. This dosing regimen is expected to provi...

$Kronos Bio (KRON.US)$
NEWS
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...

$Kronos Bio (KRON.US)$ Kronos Bio Says Phase 1b Portion Of Phase 1b/2 Lanraplenib Study Does Not Support Continuing To Phase 2